Aspira Pathlab & Diagnostics Ltd
Incorporated in 1973, Aspira Pathlab & Diagnostics Ltd is in the business of pathology and related healthcare services[1]
- Market Cap ₹ 122 Cr.
- Current Price ₹ 118
- High / Low ₹ 136 / 49.0
- Stock P/E 50.7
- Book Value ₹ 7.02
- Dividend Yield 0.00 %
- ROCE 17.0 %
- ROE 33.0 %
- Face Value ₹ 10.0
Pros
- Debtor days have improved from 50.5 to 39.0 days.
- Promoter holding has increased by 28.2% over last quarter.
- Company's working capital requirements have reduced from 19.6 days to 14.1 days
Cons
- Stock is trading at 16.8 times its book value
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|
| 13.20 | 22.00 | 22.62 | |
| 14.38 | 18.49 | 19.15 | |
| Operating Profit | -1.18 | 3.51 | 3.47 |
| OPM % | -8.94% | 15.95% | 15.34% |
| 0.42 | 0.36 | 0.41 | |
| Interest | 0.37 | 0.35 | 0.00 |
| Depreciation | 1.54 | 1.49 | 1.49 |
| Profit before tax | -2.67 | 2.03 | 2.39 |
| Tax % | 0.00% | 0.00% | |
| -2.67 | 2.02 | 2.40 | |
| EPS in Rs | -2.59 | 1.96 | 2.33 |
| Dividend Payout % | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 67% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 177% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 27% |
| 3 Years: | 65% |
| 1 Year: | 79% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 33% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Equity Capital | 10.29 | 10.29 |
| Reserves | -5.08 | -3.06 |
| 7.71 | 8.13 | |
| 1.79 | 2.11 | |
| Total Liabilities | 14.71 | 17.47 |
| 6.79 | 6.53 | |
| CWIP | 0.00 | 0.00 |
| Investments | 0.00 | 0.08 |
| 7.92 | 10.86 | |
| Total Assets | 14.71 | 17.47 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| 1.05 | 1.83 | |
| 0.14 | 0.12 | |
| -0.95 | -0.99 | |
| Net Cash Flow | 0.24 | 0.95 |
| Free Cash Flow | 0.79 | 1.66 |
| CFO/OP | -89% | 52% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Debtor Days | 61.94 | 38.99 |
| Inventory Days | 62.69 | 50.31 |
| Days Payable | 101.70 | 73.00 |
| Cash Conversion Cycle | 22.93 | 16.30 |
| Working Capital Days | 25.16 | 14.10 |
| ROCE % | 17.04% |
Insights
In beta| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Number of Permanent Employees employees ・Standalone data |
|
|||||
| B2B Revenue Share % of revenue ・Standalone data |
||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Resignation of Director
25 Jul - Vaibhav Odhekar resigns as Additional Executive Director effective close of business July 25, 2026.
-
Announcement under Regulation 30 (LODR)-Change in Directorate
25 Jul - Mr. Vaibhav Odhekar resigned as Additional Executive Director effective close of business July 25, 2026.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
13 Jul - Compliance Certificate in accordance with regulation 74(5) of SEBI (DP) regulation 2018 for quarter ended 30th June 2026
-
Closure of Trading Window
24 Jun - Trading window closes July 1, 2026 until Q1 FY27 results and 48 hours thereafter.
-
Disclosure Under Regulation 30(LODR) For Classification Of Mr. Nikunj Mange And Mr. Jay Arvind Bhanushali As Promoters Of The Company
11 Jun - Open offer completed on June 11, 2026; Nikunj Mange and Jay Bhanushali classified as promoters.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1][2][3]
Aspira Pathlab & Diagnostics Ltd (APDL) provides pathology and radiology investigation services through diagnostic centers in Mumbai. Serving B2B and B2C markets, the company offers diagnostic solutions to individual patients, hospitals, healthcare providers, and businesses.